Heidemarie Lex1, Yarden Ginsburg2, Adam F Sitzmann2, Clara Grayhack2, Daniel F Maixner2, Brian J Mickey3. 1. Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address: heidi.lex@hsc.utah.edu. 2. Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI, USA. 3. Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT, USA; Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: brian.mickey@utah.edu.
Abstract
BACKGROUND: Treatment-resistant depression affects millions of people worldwide and is a leading cause of disability and suicide. Studies of treatment-resistant depression outcomes have traditionally focused on depressive symptoms and functional impairment. Quality of life (QoL) has not been well described. We aimed to measure QoL in individuals with treatment-resistant depression and to determine how QoL was related to traditional measures of symptoms and social functioning. METHODS: We used a reliable, cross-culturally validated questionnaire, the abbreviated World Health Organization Quality of Life scale (WHOQOL-BREF), to prospectively measure QoL in 79 patients with treatment-resistant depression who were referred for electroconvulsive therapy at a United States tertiary-care medical center. QoL was characterized in four domains: physical, psychological, social, and environmental. QoL domains were examined for association with demographic variables, patient-reported depressive symptoms, functional impairment, and childhood adversity, as well as clinician-rated scales. RESULTS: Relative to published international norms, mean QoL scores were low in physical (standardized score, z = -2.0), psychological (z = -2.6), and social (z = -1.0) domains, but not in the environmental domain (z = 0.2). After controlling for age and income, patient-rated depressive symptoms correlated with physical (Pearson correlation, r = -0.26) and psychological (r = -0.43) QoL, whereas adverse childhood experiences correlated with environmental QoL (r = -0.33). Patient-rated functional impairment correlated modestly with all domains (r = -0.25 to -0.39). Surprisingly, QoL correlated very weakly with clinician-rated measures. These modest associations of QoL with other clinical scales were confirmed in multiple regression analyses. LIMITATIONS: We used a single QoL instrument, which did not allow us to directly compare the WHOQOL-BREF scale with other commonly used instruments. Our sample was recruited from a single academic medical center in the Midwest region of the United States and was largely Caucasian. These factors may limit generalizability to other settings and ethnicities. CONCLUSION: Among individuals with treatment-resistant depression, QoL is lowest in the psychological and physical domains. QoL is only modestly correlated with patient-rated symptoms and functioning, and even more weakly correlated with clinician-rated scales, indicating that measures of symptoms and functioning cannot serve as QoL proxies. QoL should be assessed when caring for patients with treatment-resistant depression. When developing novel biological, psychological, and social interventions for treatment-resistant depression, QoL should be targeted as a distinct clinical outcome.
BACKGROUND: Treatment-resistant depression affects millions of people worldwide and is a leading cause of disability and suicide. Studies of treatment-resistant depression outcomes have traditionally focused on depressive symptoms and functional impairment. Quality of life (QoL) has not been well described. We aimed to measure QoL in individuals with treatment-resistant depression and to determine how QoL was related to traditional measures of symptoms and social functioning. METHODS: We used a reliable, cross-culturally validated questionnaire, the abbreviated World Health Organization Quality of Life scale (WHOQOL-BREF), to prospectively measure QoL in 79 patients with treatment-resistant depression who were referred for electroconvulsive therapy at a United States tertiary-care medical center. QoL was characterized in four domains: physical, psychological, social, and environmental. QoL domains were examined for association with demographic variables, patient-reported depressive symptoms, functional impairment, and childhood adversity, as well as clinician-rated scales. RESULTS: Relative to published international norms, mean QoL scores were low in physical (standardized score, z = -2.0), psychological (z = -2.6), and social (z = -1.0) domains, but not in the environmental domain (z = 0.2). After controlling for age and income, patient-rated depressive symptoms correlated with physical (Pearson correlation, r = -0.26) and psychological (r = -0.43) QoL, whereas adverse childhood experiences correlated with environmental QoL (r = -0.33). Patient-rated functional impairment correlated modestly with all domains (r = -0.25 to -0.39). Surprisingly, QoL correlated very weakly with clinician-rated measures. These modest associations of QoL with other clinical scales were confirmed in multiple regression analyses. LIMITATIONS: We used a single QoL instrument, which did not allow us to directly compare the WHOQOL-BREF scale with other commonly used instruments. Our sample was recruited from a single academic medical center in the Midwest region of the United States and was largely Caucasian. These factors may limit generalizability to other settings and ethnicities. CONCLUSION: Among individuals with treatment-resistant depression, QoL is lowest in the psychological and physical domains. QoL is only modestly correlated with patient-rated symptoms and functioning, and even more weakly correlated with clinician-rated scales, indicating that measures of symptoms and functioning cannot serve as QoL proxies. QoL should be assessed when caring for patients with treatment-resistant depression. When developing novel biological, psychological, and social interventions for treatment-resistant depression, QoL should be targeted as a distinct clinical outcome.
Authors: Roger S McIntyre; Marie-Josée Filteau; Lawrence Martin; Simon Patry; Andre Carvalho; Danielle S Cha; Maxime Barakat; Maia Miguelez Journal: J Affect Disord Date: 2013-11-15 Impact factor: 4.839
Authors: Laia Mas-Expósito; Juan Antonio Amador-Campos; Juana Gómez-Benito; Lluís Lalucat-Jo Journal: Qual Life Res Date: 2011-02-03 Impact factor: 4.147
Authors: David L Dunner; A John Rush; James M Russell; Michael Burke; Stacy Woodard; Peggy Wingard; John Allen Journal: J Clin Psychiatry Date: 2006-05 Impact factor: 4.384
Authors: Daniel Zahra; Adam Qureshi; William Henley; Rod Taylor; Cath Quinn; Jill Pooler; Gillian Hardy; Alexandra Newbold; Richard Byng Journal: Int J Psychiatry Clin Pract Date: 2014-03-16 Impact factor: 1.812
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Emma Morton; Venkat Bhat; Peter Giacobbe; Wendy Lou; Erin E Michalak; Shane McInerney; Trisha Chakrabarty; Benicio N Frey; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Susan Rotzinger; Sidney H Kennedy; Raymond W Lam Journal: CNS Drugs Date: 2021-04-16 Impact factor: 5.749
Authors: Heidemarie Lex; Steven W Nevers; Erica L Jensen; Yarden Ginsburg; Daniel F Maixner; Brian J Mickey Journal: J Affect Disord Date: 2021-05-18 Impact factor: 6.533
Authors: Carmen Galán-Arroyo; Damián Pereira-Payo; Ángel Denche-Zamorano; Miguel A Hernández-Mocholí; Eugenio Merellano-Navarro; Jorge Pérez-Gómez; Jorge Rojo-Ramos; José Carmelo Adsuar Journal: Int J Environ Res Public Health Date: 2022-03-10 Impact factor: 3.390